Christopher John Mathews

Novel palladium imidazole catalysts for Suzuki cross-coupling reactions

Novel palladium imidazole catalytic systems for the Suzuki cross-coupling reaction have been developed from commercially available and inexpensive imidazoles and palladium sources, and exhibit high activity and no homo-coupling.

Palladium catalysed Suzuki cross-coupling reactions in ambient temperature ionic liquids

Palladium catalysed Suzuki cross-coupling reactions have been conducted in the ambient temperature ionic liquid,1-butyl-3-methylimidazolium tetrafluoroborate ([bmim][BF4]), exhibiting unprecedented reactivities in addition to easy product isolation and catalyst recycling.

Risk-adjusted colorectal cancer screening using the FIT and routine screening data: development of a risk prediction model

Background:The faecal immunochemical test (FIT) is replacing the guaiac faecal occult blood test in colorectal cancer screening. Increased uptake and FIT positivity will challenge colonoscopy services. We developed a risk prediction model combining routine screening data with FIT concentration to improve the accuracy of screening referrals.Methods:Multivariate analysis used complete cases of those with a positive FIT (⩾20 μg g−1) and diagnostic outcome (n=1810; 549 cancers and advanced adenomas). Logistic regression was used to develop a risk prediction model using the FIT result and screening data: age, sex and previous screening history. The model was developed further using a feedforward neural network. Model performance was assessed by discrimination and calibration, and test accuracy was investigated using clinical sensitivity, specificity and receiver operating characteristic curves.Results:Discrimination improved from 0.628 with just FIT to 0.659 with the risk-adjusted model (P=0.01). Calibration using the Hosmer–Lemeshow test was 0.90 for the risk-adjusted model. The sensitivity improved from 30.78% to 33.15% at similar specificity (FIT threshold of 160 μg g−1). The neural network further improved model performance and test accuracy.Conclusions:Combining routinely available risk predictors with the FIT improves the clinical sensitivity of the FIT with an increase in the diagnostic yield of high-risk adenomas.